NVCT vs. MRNA

Last updated Jun 6, 2026

NVCT (Nuvectis Pharma Inc) and MRNA (Moderna, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, NVCT returned -17.81%/yr vs -27.96%/yr for MRNA. At a 0.18 correlation, their price movements are largely independent.

Performance

NVCT vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nuvectis Pharma Inc (NVCT) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, NVCT achieves a 26.36% return, which is significantly lower than MRNA's 60.87% return.

NVCT

• 1D: -1.34%
• 1M: -7.56%
• YTD: 26.36%
• 6M: 42.18%
• 1Y: 7.80%
• 3Y*: -17.81%
• 5Y*: —
• 10Y*: —

MRNA

• 1D: -8.04%
• 1M: -2.27%
• YTD: 60.87%
• 6M: 71.26%
• 1Y: 72.76%
• 3Y*: -27.96%
• 5Y*: -25.45%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

NVCT vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
NVCT Nuvectis Pharma Inc	26.36%	39.56%	-35.13%	11.20%	130.77%
MRNA Moderna, Inc.	60.87%	-29.08%	-58.19%	-44.63%	10.19%

Correlation

The correlation between NVCT and MRNA is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.27
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (All Time) Calculated using the full available price history since Feb 7, 2022	0.18

Fundamentals

Market Cap NVCT : $223.37M MRNA : $18.74B
EPS NVCT : -$1.22 MRNA : -$8.16
PB Ratio NVCT : 15.71 MRNA : 2.53
Total Revenue (TTM) NVCT : $0.00 MRNA : $2.23B
Gross Profit (TTM) NVCT : $0.00 MRNA : -$309.00M
EBITDA (TTM) NVCT : -$22.01M MRNA : -$3.02B

Return for Risk

NVCT vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVCT

NVCT Risk / Return Rank: 45
NVCT Sharpe Ratio Rank: 46
NVCT Sortino Ratio Rank: 45
NVCT Omega Ratio Rank: 43
NVCT Calmar Ratio Rank: 46
NVCT Martin Ratio Rank: 46

MRNA

MRNA Risk / Return Rank: 75
MRNA Sharpe Ratio Rank: 78
MRNA Sortino Ratio Rank: 77
MRNA Omega Ratio Rank: 71
MRNA Calmar Ratio Rank: 77
MRNA Martin Ratio Rank: 73

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NVCT vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nuvectis Pharma Inc (NVCT) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NVCT	MRNA	Difference
Sharpe ratio: Return per unit of total volatility	0.11	1.27	-1.16
Sortino ratio: Return per unit of downside risk	0.60	2.11	-1.51
Omega ratio: Gain probability vs. loss probability	1.07	1.24	-0.17
Calmar ratio: Return relative to maximum drawdown	0.17	2.31	-2.14
Martin ratio: Return relative to average drawdown	0.31	4.57	-4.26
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NVCT vs. MRNA - Sharpe Ratio Comparison

The current NVCT Sharpe Ratio is 0.11, which is lower than the MRNA Sharpe Ratio of 1.27. The chart below compares the historical Sharpe Ratios of NVCT and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	NVCT	MRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.11	1.27	-1.16
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.38	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.26	0.19	+0.07

Drawdowns

NVCT vs. MRNA - Drawdown Comparison

The maximum NVCT drawdown since its inception was -77.89%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for NVCT and MRNA.

Drawdown Indicators

	NVCT	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-77.89%	-95.38%	+17.49%
Max Drawdown (1Y) Largest decline over 1 year	-37.36%	-35.51%	-1.85%
Max Drawdown (3Y) Largest decline over 3 years	-75.43%	-86.58%	+11.15%
Max Drawdown (5Y) Largest decline over 5 years	—	-95.38%	—
Current Drawdown Current decline from peak	-53.33%	-90.21%	+36.88%
Average Drawdown Average peak-to-trough decline	-53.27%	-56.68%	+3.41%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.86%	17.94%	+2.92%

Volatility

NVCT vs. MRNA - Volatility Comparison

Nuvectis Pharma Inc (NVCT) has a higher volatility of 24.63% compared to Moderna, Inc. (MRNA) at 20.16%. This indicates that NVCT's price experiences larger fluctuations and is considered to be riskier than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NVCT	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	24.63%	20.16%	+4.47%
Volatility (6M) Calculated over the trailing 6-month period	41.52%	48.81%	-7.29%
Volatility (1Y) Calculated over the trailing 1-year period	57.21%	64.58%	-7.37%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	109.53%	66.46%	+43.07%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	109.53%	71.97%	+37.56%

Dividends

NVCT vs. MRNA - Dividend Comparison

Neither NVCT nor MRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both NVCT and MRNA in my portfolio?

NVCT and MRNA have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, NVCT or MRNA?

NVCT has higher volatility (24.63%) compared to MRNA (20.16%). In terms of maximum drawdown, NVCT dropped -77.89% vs MRNA's -95.38%.

Which has better risk-adjusted returns?

MRNA currently has the higher Sharpe Ratio (1.27 vs 0.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.